Pediatric Crohn’s Disease News and Research

RSS
First clinical study for development of SGX203 to treat pediatric Crohn's disease

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Bone age necessary to correctly interpret growth status in pediatric Crohn's disease

Bone age necessary to correctly interpret growth status in pediatric Crohn's disease

Measuring bone age should be part of routine care for pediatric patients with Crohn's disease

Measuring bone age should be part of routine care for pediatric patients with Crohn's disease

Soligenix first quarter revenues decrease to $647,418

Soligenix first quarter revenues decrease to $647,418

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

Soligenix third quarter revenues increase to $5,796,000

Soligenix third quarter revenues increase to $5,796,000

New tool for predicting disease course in children with Crohn's disease

New tool for predicting disease course in children with Crohn's disease

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Schering-Plough announces 2009 third quarter financial results

Schering-Plough announces 2009 third quarter financial results

Inflammatory bowel disease on the rise in specific populations

Inflammatory bowel disease on the rise in specific populations

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott opens biotech facility in Puerto Rico

Abbott opens biotech facility in Puerto Rico

Arthritis drug wins approval for use in children with Crohn's disease

Arthritis drug wins approval for use in children with Crohn's disease